Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (Q46537963)

From Wikidata

Jump to navigation Jump to search

scientific article published in April 1995

Language	Label	Description	Also known as
English	Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome	scientific article published in April 1995

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

Cytomegalovirus

0 references

cytomegalovirus retinitis

1 reference

based on heuristic

inferred from title

author name string

L S Kirsch

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

J F Arevalo

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

E De Clercq

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

E Chavez de la Paz

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

D Munguia

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

R Garcia

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

W R Freeman

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

language of work or name

0 references

publication date

1 April 1995

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

American Journal of Ophthalmology

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

119

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

466-476

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Ophthalmic Involvement in Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Long-term visual morbidity of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Acquired immune deficiency syndrome. Ocular manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Ocular manifestations of acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Cytomegalovirus retinitis and acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

A novel selective broad-spectrum anti-DNA virus agent

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Useful adjuncts for vitreoretinal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue (S)-HPMPApp: influence of the adenovirus DNA binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Treatment of cytomegalovirus retinitis with ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2814%2971233-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9394(14)71233-4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/7709971

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46537963&oldid=2116933807"